Furthermore, p53 deficiency and continuous increase of myeloma growth factors could influence the mTOR signaling pathway by changing the metabolic processes of tumor cells, promoting tumor progression and drug resistance in MM (Falank et al., 2016; Manier et al., 2017). The gene discussed is TP53; the disease is neoplasm.